European Guideline (EuroGuiDerm) on atopic eczema: Living update
EuroGuiDerm/EADV · 2025 · Europe
Source and licence
- Authors
- A. Wollenberg, M. Kinberger, B. Arents et al.
- Title
- European Guideline (EuroGuiDerm) on atopic eczema: Living update
- Journal
- Journal of the European Academy of Dermatology and Venereology, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC12376260
Licence statement of the original publication
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
Verbatim, with grade of recommendation or strength of consensus where given.
Dosage: acute flare, short term, long term
- We recommend combining AZA, as any systemic treatment, with emollients and, whenever needed, topical anti‐inflammatory treatment in AE patients.
Dosage: Acute flare, short term, long term
- We recommend combining ciclosporin, as any systemic treatment, with emollients and, whenever needed, topical anti‐inflammatory treatment in AE patients
- We recommend combining systemic glucocorticosteroids, as any systemic treatment, with emollients and, whenever needed, topical anti‐inflammatory treatments in AE patients.
- We recommend combining MTX, as any systemic treatment, with emollients and, whenever needed, topical anti‐inflammatory treatment in AE patients.
Abstract
The evidence‐ and consensus‐based living guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. The original EuroGuiDerm Guideline on atopic eczema was published in June 2022. Since then, the part of the guideline dealing with systemic therapy has been updated twice. This paper summarizes the results of the second update. Twenty‐eight experts (including clinicians and patient representatives) from 12 European countries participated. The updated guideline provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab and tralokinumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib and upadacitinib). Additionally, the updated guidelines address considerations for paediatric, adolescent, pregnant and breastfeeding patients. For all other aspects, please refer to the 2022 version.
Contents of the original publication
The section headings of the original.
- METHODS
- Evidence
- OVERVIEW OF RECOMMENDATIONS
- INTRODUCTION TO SYSTEMIC TREATMENT
- CONVENTIONAL SYSTEMIC DRUGS
- Azathioprine
- Ciclosporin
- Systemic glucocorticosteroids
- Methotrexate
- Mycophenolate mofetil
- BIOLOGICS
- Dupilumab
- Lebrikizumab
- Nemolizumab
- Tralokinumab
- Omalizumab
- JAK‐INHIBITORS
- Special considerations
- General safety issues
- Monitoring
- Pregnancy
- Abrocitinib
- Baricitinib
- Upadacitinib
- PREGNANCY, BREASTFEEDING AND FAMILY PLANNING
- Pregnant women
- Specific consideration for breastfeeding women
- Family planning
- ETHICAL APPROVAL
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint